A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study

Trial Profile

A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2016

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Dexamethasone; Folic acid; Gemcitabine; Vitamin B12 analogues
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms AP/GP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top